New York, USA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The Global Infectious Disease Diagnostics Market to Register Growth at a Paltry CAGR of 3.80% by 2027, Assesses DelveInsight
The infectious disease diagnostics market is expected to prosper as a result of factors such as the increasing prevalence of infectious diseases such as COVID-19, malaria, typhoid, and others, rising incidences of epidemics and pandemics, and a growing focus on improving the safety, affordability, and usability of infectious disease diagnostics for end-users.
DelveInsight’s Infectious Disease Diagnostics Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, infectious disease diagnostics market drivers, barriers, and trends, and key infectious disease diagnostics companies in the market.
Key Takeaways from the Infectious Disease Diagnostics Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global infectious disease diagnostics market during the forecast period.
- Notable infectious disease diagnostics companies such as BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., bioMérieux SA, Abbott, QIAGEN, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC, Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and several others are currently operating in the infectious disease diagnostics market.
- In May 2022, BD announced the launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the US.
- In December 2021, Roche announced the launch of the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.
- In March 2020, Abbott announced that the U.S. Food and Drug Administration (FDA) had issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.
To read more about the latest highlights related to the infectious disease diagnostics market, get a snapshot of the key highlights entailed in the Global Infectious Disease Diagnostics Market Report
Infectious Disease Diagnostics Overview
Infectious disease diagnosis is defined as a laboratory test used to diagnose infectious diseases with the assistance of skilled technicians and physicians. It is a diagnostic procedure that identifies and characterizes the causative organism of an infectious disease.
Infectious disease diagnostics include diagnostic tests, assays, instruments, and other tools used to detect and identify the causative agents of the disease. Various diagnosis procedures and instruments are used to analyze a sample of blood, urine, mucus, or other body fluids to provide information about the causative organism.
Learn more about infectious disease diagnostics @Infectious Disease Diagnostic Tests
Infectious Disease Diagnostics Market Insights
North America is expected to lead the global infectious disease diagnostics market in terms of revenue generation. This can be attributed to the presence of a large patient pool associated with infectious diseases such as sexually transmitted diseases (STDs), tuberculosis (TB), and others, as well as a highly potent market in terms of product development and launches, among other factors.
Furthermore, the presence of key market players such as BD, Abbott, and Thermo Fisher Scientific Inc., among others, as well as ongoing regulatory approvals, are expected to drive up demand for infectious disease diagnostics. For example, DiaSorin received US FDA 510(k) clearance for the LIAISON® MeMed BV® Test in July 2022, which is intended to differentiate between viral and bacterial infections.
To know more about why North America is leading the market growth in the infectious disease diagnostics market, get a snapshot of the Infectious Disease Diagnostics Market Trends
Infectious Disease Diagnostics Market Dynamics
Among the notable drivers of the infectious disease diagnostics market, the rising prevalence of infectious diseases appears to be the most important factor for propelling the infectious disease diagnostics market. Furthermore, rising epidemics and pandemics around the world will drive market growth for infectious disease diagnostics. Moreover, the rising malaria prevalence is another major factor driving the growth of the infectious disease diagnostics market.
On the other hand, the risk of blood sample contamination during transport and storage, a scarcity of skilled phlebotomists, and the high cost of diagnostic tests may act as restraints on the infectious disease diagnostics market growth.
Additionally, the infectious disease diagnostics market experienced a brief period of market restraint during the early stages of the pandemic due to the implementation of lockdown as necessary measures to prevent the spread of COVID-19 infection, which resulted in the suspension of routine diagnostic checkups. Furthermore, during the initial phases of the lockdown, the manufacturing and supply of diagnostic kits, among other things, were hampered, resulting in the further market decline. However, as the number of COVID-19 cases increased, the demand for COVID-19 testing, as well as tests for other respiratory diseases, increased, resulting in a slight improvement in the infectious disease diagnostics market.
Moreover, with the resumption of activities such as diagnostic tests for other infectious diseases and others across industries, including the healthcare sector, the infectious disease diagnostics market is expected to grow during the forecast period of 2022–2027.
Get a sneak peek at the infectious disease diagnostics market dynamics @Infectious Disease Diagnostics Market Dynamics Analysis
| Report Metrics | Details |
| Coverage | Global |
| Study Period | 2019–2027 |
| Base Year | 2021 |
| Market CAGR | 3.80% |
| Projected Infectious Disease Diagnostics Market Size by 2027 | USD 48.10 Billion |
| Key Infectious Disease Diagnostics Companies | BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., bioMérieux SA, Abbott, QIAGEN, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC, Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others |
Infectious Disease Diagnostics Market Assessment
- Infectious Disease Diagnostics Market Segmentation
-
- Market Segmentation By Type: Products (Instruments, Reagents And Kits) and Services
- Market Segmentation By Technology: Genetic Material Based, Immunoassays, Microbial Cultures, and Others
- Market Segmentation By Application: Viral Diseases, Bacterial Diseses, and Others
- Market Segmentation By End User: Hosptials, Diagnostic Labs, and Others
- Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the infectious disease diagnostics market are set to emerge as the trendsetter explore @Infectious Disease Diagnostics Companies
Table of Contents
| 1 | Report Introduction |
| 2 | Executive summary |
| 3 | Regulatory and Patent Analysis |
| 4 | Key Factors Analysis |
| 5 | Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on Infectious Disease Diagnostics Market |
| 7 | Infectious Disease Diagnostics Market Layout |
| 8 | Global Company Share Analysis – Key 3-5 Companies |
| 9 | Infectious Disease Diagnostics Market Company and Product Profiles |
| 10 | Project Approach |
| 11 | About DelveInsight |
Interested in knowing the infectious disease diagnostics market by 2027? Click to get a snapshot of the Infectious Disease Diagnostics Market Research
Related Reports
Community-acquired Bacterial Pneumonia Epidemiology
Community-acquired Bacterial Pneumonia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted community-acquired bacterial pneumonia epidemiology in the 7MM.
Community-acquired Bacterial Pneumonia Pipeline
Community-acquired Bacterial Pneumonia Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key community-acquired bacterial pneumonia companies, including Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, among others.
Community-acquired Pneumonia Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key community-acquired pneumonia companies, including Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, among others.
Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market
Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Hospital-acquired and ventilator-associated bacterial pneumonia companies including Duke University, Sinovent Pty Ltd., Cumberland Pharmaceuticals, among others.
Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial pneumonia companies, including Shionogi, Merck Sharp & Dohme Corp., among others.
Pneumonia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pneumonia companies including Pfizer, Affinivax, Merck Sharp &Dohme Corp., Vaxcyte, among others.
Other Trending Reports
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
